Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Sep 7;28(9):746-749.
doi: 10.1093/oncolo/oyad047.

The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice

Georges Gebrael  1 , Vinay Mathew Thomas  1 , Umang Swami  1 , Neeraj Agarwal  1
Affiliations
Comment

The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice

Georges Gebrael et al. Oncologist. .

Abstract

This commentary highlights 2 international studies on real-world treatment trends and patterns among patients with metastatic castration-sensitive and resistant prostate cancer and how interventions targeting physicians and patients can bridge the gap between evidence-based medicine and real-world practice.

PubMed Disclaimer

Conflict of interest statement

Neeraj Agarwal reports consultancy (lifetime association) to Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics; and also reports institutional research funding from AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, GlaxoSmithKline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. Umang Swami reports consultancy to Astellas, Exelixis, Seattle Genetics, Imvax, AstraZeneca, and Sanofi and research funding to institute from Janssen, Exelixis, and Astellas/Seattle Genetics. The other authors indicated no financial relationships.

Comment on

References

    1. Sweeney CJ, Chen YH, Carducci M, et al. . Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737-746. 10.1056/NEJMoa1503747. - DOI - PMC - PubMed
    1. Fizazi K, Tran N, Fein L, et al. ; LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352-360. 10.1056/NEJMoa1704174. - DOI - PubMed
    1. Fizazi K, Tran N, Fein L, et al. . Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686-700. 10.1016/S1470-2045(19)30082-8. - DOI - PubMed
    1. Chi KN, Agarwal N, Bjartell A, et al. ; TITAN Investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13-24. 10.1056/NEJMoa1903307. - DOI - PubMed
    1. Chi KN, Chowdhury S, Bjartell A, et al. . Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294-2303. 10.1200/JCO.20.03488. - DOI - PubMed